U.S., July 12 -- ClinicalTrials.gov registry received information related to the study (NCT07060638) titled 'Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) Trial' on June 10.
Brief Summary: This is a multicenter, randomized, double-blinded, placebo-controlled trial focused on the treatment of severe alcohol-associated hepatitis (sAH) and alcohol use disorder (AUD).
The primary purpose of the study is to determine whether subjects receiving sAH therapy in addition to AUD treatments will have better alcohol and liver-related outcomes at 6 months compared to sAH therapy plus usual care for AUD. Patients assigned to the AUD treatment will receive Acamprosate and counseling whereas those assigned to AUD stand...